RGEN

Biopharma manufacturing company Repligen Corporation (NASDAQ:RGEN) reported revenue ahead of Wall Street’s expectations in Q3 2026, with sales up 10.9% year on year to $209.3 million.

Repligen’s third quarter was marked by revenue and non-GAAP profit that exceeded Wall Street expectations, driving a positive market reaction.

Conestoga Capital Advisors, an asset management company, released its third-quarter 2026 investor letter. The letter can be downloaded here.

Wasatch Global Investors, an asset management company, released its “Small Cap Growth Strategy” Q3 2026 investor letter. The letter can be downloaded here.

Repligen (RGEN) just booked record third quarter revenue of US$209.31 million, raised full year sales guidance, and leaned on its BioLife acquisition, even as impairment driven losses kept headline earnings in the red.

Repligen reported record Q3 2026 revenue of US$209.31 million and nine-month revenue of US$607.7 million, while posting net losses for both periods, including a US$41.24 million intangible asset impairment in the quarter.

Repligen (NasdaqGS:RGEN) reported its latest quarterly results with significant intangible asset impairment charges recorded in the period. The company moved from prior net income to a net loss for the quarter, driven in part by these impairment expenses.

Repligen has delivered a 57.8% gain over the past three years, which puts real weight on the question of whether today's share price lines up with the cash the business is expected to generate over time.

Moby summary of Repligen Corporation's Q3 2026 earnings call